Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 24 Issue 7, July 2006

Colored scanning electron micrograph (SEM) of dividing Schizosaccharomyces pombe cells. Matsuyama et al. have cloned and partially characterized all protein-encoding open reading frames (the ORFeome) of fission yeast (p 841). Credit: Steve Gschmeissner/Science Photo Library.

Volume 24 Issue 7

Subscribe

Editorial

Top of page ⤴

News

  • A flurry of investment activity during the first months of 2006 is evidence that some investors are waking up to the untapped market potential of a range of widely occurring gastrointestinal (GI) conditions that are as yet not well served.

    • Cormac Sheridan
    News

  • Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option on 3 of 12 specified products in development.

    • John Ransom
    News

  • In May, Merck, one of the oldest and stodgiest pharmaceutical companies, entered the biotech arena by announcing its plans to purchase two protein manufacturing firms: GlycoFi for $400 million and Abmaxis for $80 million.

    • Jim Kling
    News

  • The US Securities and Exchange Commission (SEC) has heard the plea of small biotechs that are overwhelmed by Sarbanes-Oxley (SOX) financial accounting compliance costs.

    • Stacy Lawrence
    News
Top of page ⤴

News in Brief

Top of page ⤴

News

  • Passion and perseverance have seen Elliot Entis down the long road of bringing transgenic salmon to market. His experiences 'swimming upstream' in animal biotech shows that endurance is key in bringing pioneering technologies to market.

    • Kendal Powell
    News
Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Ariad Pharmaceuticals's victory against Lilly on NF-κB patent infringement has drug companies and legal experts wondering about the future of biotech patenting. Ken Garber reports on the aftermath of the surprising decision.

    • Ken Garber
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Biofuels have been touted before, but failed to deliver. What's needed to get it right this time around?

    • Stephan Herrera
    Commentary

  • Is the introduction of renewable biofuels a simple problem of technology development and diffusion or does it require an industrial revolution?

    • Alain A Vertès
    • Masayuki Inui
    • Hideaki Yukawa
    Commentary

  • A substantial increase in political and financial investment that aligns plant and industrial biotech will pay dividends for sustainable energy and materials production.

    • Michael W Bevan
    • Maurice C R Franssen
    Commentary
Top of page ⤴

Investors Lab

Top of page ⤴

Feature

  • The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.

    • Gary Walsh
    Feature

  • Today, ethanol and biodiesel are predominantly produced from corn kernels, sugarcane or soybean oil. But researchers and investors are increasingly upbeat about another biofuel feedstock, lignocellulose—the most abundant biological material on earth.

    • Charlotte Schubert
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • A new community resource for fission yeast offers genome-wide data on open reading frames (ORFs) and protein localization.

    • Shelley Sazer
    News & Views

  • A consensus epitope prediction approach identifies the epitopes responsible for 95% of the murine T-cell response to vaccinia virus.

    • Leonard Moise
    • Anne S De Groot
    News & Views

  • Proteins that could not be displayed on the surface of phage are now amenable to this powerful selection technology.

    • Damon Huber
    • Jonathan Beckwith
    News & Views

  • Inhibitors of the PI3 kinase family of enzymes show promise for treating brain tumors.

    • Paul Workman
    • Paul A Clarke
    • Florence I Raynaud
    News & Views

  • A new animal study shows that too much RNAi is lethal.

    • Sailen Barik
    News & Views
Top of page ⤴

Commentary

  • Developing and deploying specialized computing systems for specific research communities is achievable, cost effective and has wide-ranging benefits.

    • Dawn Field
    • Bela Tiwari
    • Milo Thurston
    Commentary
Top of page ⤴

Analysis

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links